

10 April 2025

MYCELX Technologies Corporation
("MYCELX" or the "Company") (AIM: MYX)

Grant of Share Options

The Company announces the grant of share options over the Company's common shares of US 0.025 each ("Common Shares") under the 2011 MYCELX Omnibus Performance Incentive Plan which was extended at the 2019 Annual Meeting (the "Plan").

Details of the awards to a Director and one PDMR on 9 April 2025 together with their current beneficial holdings of Common Shares are presented below:

Grant of Share Options to Chief Financial Officer

Name	Number of share options granted	Exercise price	Total number of share options held following this notification	Total number of share options as % of current issued share capital
Kimberly Slayton	25,000	US 0.31*	331,667	1.36%

Ms. Slayton holds no Common Shares in the issued capital of the Company.

Grant of Share Options to Chief Executive Officer

Name	Number of share options granted	Exercise price	Total number of share options held following this notification	Total number of share options as % of current issued share capital
Connie Mixon	25,000	US 0.31*	275,000	1.13%

In addition, following this award, Connie Mixon continues to be interested in 2,931,576 Common Shares, representing 12.03 per cent of the present issued capital of the Company.

The aggregate number of Common Shares held by Ms. Mixon also includes (a) 150,000 shares held by limited liability companies controlled by Ms. Mixon; and (b) 202,646 shares held by or on behalf of Ms. Mixon's children.

The above grants formed part of wider grants of, in aggregate, 200,000 options to employees across the Company, on the same date, representing 0.82% of the current issued share capital.

These share options granted on 9 April 2025 will vest as to 50% on 31 December 2025 and 50% on 31 December 2026, and must be exercised prior to the tenth anniversary of the vesting date, subject to the restrictions on dealing under the Company's share dealing code.

Following the above grants, a total of 1,506,668 share options have been granted to directors, employees and consultants and are currently outstanding, representing 6.18% of the issued share capital of 24,363,814 Common Shares.

*Based on the closing mid-market price of the Company's Common Shares at 8 April 2025, and the closing US/£ exchange rate at that date.

Details of the transactions are reported in the PDMR notifications below:

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Kimberly Slayton
2	Reason for the notification	
a)	Position/status	Chief Financial Officer

a)	Position/status	Chief Financial Officer	
b)	Initial notification/Amendment	Initial Notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	MYCELX Technologies Corporation	
b)	LEI	213800UJZINIK2VD1G48	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Grant of options over 25,000 common shares of US 0.025 each. ISIN: US62847T2024	
c)	Currency	US	
d)	Price(s) and volumes(s)	Price(s)	Volume(s)
		US 0.31	25,000
e)	Aggregated information - Aggregated volume - Price	As above	
f)	Date of the transaction	9 April 2025	
g)	Place of the transaction	N/A (grant of options)	

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Connie Mixon	
2	Reason for the notification		
a)	Position/status	Director and Chief Executive Officer	
b)	Initial notification/Amendment	Initial Notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	MYCELX Technologies Corporation	
b)	LEI	213800UJZNIK2VD1G48	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Grant of options over 25,000 common shares of US 0.025 each. ISIN: US62847T2024	
c)	Currency	US	
d)	Price(s) and volumes(s)	Price(s)	Volume(s)
		US 0.31	25,000
e)	Aggregated information	As above	
	- Aggregated volume		
	- Price		
f)	Date of the transaction	9 April 2025	
g)	Place of the transaction	N/A (grant of options)	

For further information, please contact:

MYCELX Technologies Corporation
Connie Mixon, CEO
Kim Slayton, CFO

Tel: +1 888 306 6843

Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

Giles Balleny / Dan Hodgkinson (Corporate Finance)
Ondraya Swanson (Corporate Broking)
Jasper Berry / Michael Johnson (Sales)

Tel: +44 20 7220 0500

Celicourt Communications (Financial PR)

Mark Antelme
Jimmy Lea
Charlie Denley-Myerson

Tel: +44 20 7770 6424

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHIMMATMTMBMFA